spacer
home > ebr > summer 2003 > cold chain: risk, regulatory compliance and operational performance
PUBLICATIONS
European Biopharmaceutical Review

Cold Chain: Risk, Regulatory Compliance and Operational Performance

Risk assessment is, at best, an honest attempt to find a rational basis for decisions by analysing the available scientific evidence. In theory it is still an attractive ideal - to make rational decisions based on scientific evidence - because in principle it should allow diverse parties to agree on what needs to be done. However, years of actual practice have badly tarnished the ideal of risk assessment.

In the first place, the necessary data are not always available, even today. In the second place, the traditional toxicological assumptions do not always hold up under scrutiny. There is no agreement on which tests to use to determine whether someone's immune system has been damaged. There is no agreement on which tests should be used to assess damage to the nervous system. There is no agreement - and there may never be - on ways to test for genetic damage.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Sean Flanagan, the Commercial Director at Kryotrans Ltd, and Adrian Shaw, Partner at Ikon Associates

Sean Flanagan is the Commercial Director at Kryotrans Ltd. A qualified accountant, Sean has considerable financial and operational experience with a range of large and small organisations, such as United Technologies Corporation and PROTX Ltd, an Internet start-up company.

He is one of three directors at Kryotrans Ltd. He is responsible for marketing, finance, sales and administration and has also developed a number of strategic partnering relationships.


Adrian Shaw is a Partner at Ikon Associates, Marketing Consultants. Having trained in accountancy with Coopers and Lybrand, Adrian has spent the last 15 years working in the PR and marketing services world.

He has previously worked as a Director for Gavin Anderson & Co, a PR consultancy, before moving on to Burston Marsteller, where he was a Managing Director responsible for financial and corporate communications work across Europe. He now runs his own corporate brand and marketing services consultancy.


spacer
Sean Flanagan
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement

STA Pharmaceutical Co., Ltd., (WuXi STA) a subsidiary of WuXi AppTec and Dizal Pharmaceutical, a biotechnology company, announce a strategic partnership. Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Dizal Pharmaceutical for GMP production, providing integrated CMC (Chemical, manufacturing and Control) process research and manufacturing services from API to drug product.
More info >>

White Papers

Finding the Right End-to-End Safety Solution for Your Needs

Bioclinica

With upcoming changes, including the implementation of the International Conference on Harmonisation (ICH) E2B(R3) Electronic Transmission of Individual Case Safety Report and Identification of Medicinal Products (IDMP) standards, the current state of safety reporting can be confusing. Your existing safety system may not be flexible enough to accommodate these changing regulations, which are still moving targets regarding the details needed for a comprehensive solution with the right level of processes, company-to-company integrations and finalized regional rules.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement